Skip to main content

View full-text article in PMC

. 2021 Apr 20;64(7):1461–1479. doi: 10.1007/s00125-021-05442-2

Table 3.

LXR agonists that target hepatic lipid and glucose metabolism

Drug	Mechanism of action	Mode of administration	Regulatory status	Clinical effect					References
Drug	Mechanism of action	Mode of administration	Regulatory status	Steatosis	Fibrosis markers	Hepatic enzymes	HbA_1c	Insulin resistance	References
GSK2033	LXRα/LXRβ inverse agonist	–	Preclinical		=^a	NA	NA	NA	NA	[48, 55]
SR9238	LXRα/LXRβ inverse agonist	–	Preclinical		↓^a	↓^a	NA	NA	=^a	[49]
T0901317	LXRα/LXRβ agonist	–	Preclinical		↑^a	NA	NA	NA	↑^a	[48, 53]
GW3965	LXRα/LXRβ agonist	–	Preclinical		↑^a	NA	NA	NA	↑^a	[53]
BMS-852927	LXRβ agonist	PO	Phase I		=	NA	NA	NA	NA	[50]
BMS-779788	LXRα/LXRβ agonist	PO	Phase I		↑	NA	NA	NA	NA	[50]
LXR-623 (WAY 252623)	LXRα-partial/ LXRβ-full agonist	PO	Phase I		= ^a	NA	NA	NA	NA	[51, 52]

^aPreclinical data

PO, oral